Search research articles
Contact Us
Filters
Showing results (111-120 of 121) with videos related to
Page
of 13
Sort By:
International Journal of Cancer
|
September 23, 2006
Urinary biomarker profiling in transitional cell carcinoma
Nicholas P Munro, David A Cairns, Paul Clarke, et al.
Molecular and Cellular Biology
|
March 10, 2001
RNA trafficking signals in human immunodeficiency virus type 1
A J Mouland, H Xu, H Cui, et al.
Biomaterials
|
August 3, 2010
Long term culture of human embryonic stem cells on recombinant vitronectin in ascorbate free media
Andrew B J Prowse, Michael R Doran, Justin J Cooper-White, et al.
The Journal of Biological Chemistry
|
February 22, 2021
Mutational and biophysical robustness in a prestabilized monobody
Peter G Chandler, Li Lynn Tan, Benjamin T Porebski, et al.
Molecular Pharmaceutics
|
August 27, 2021
Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer
Yaowu He, Tashbib Khan, Thomas Kryza, et al.
Ebiomedicine
|
October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
Keith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
The Journal of Infectious Diseases
|
November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trial
Keith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Nature Structural & Molecular Biology
|
July 8, 2025
A nanobody-based therapeutic targeting Nipah virus limits viral escape
Ariel Isaacs, Guillermo Valenzuela Nieto, Xinghai Zhang, et al.
The Lancet. Infectious Diseases
|
April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
Keith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Molecular Psychiatry
|
November 1, 2022
SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein
Eduardo A Albornoz, Alberto A Amarilla, Naphak Modhiran, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 121) with videos related to
Sort By:
Page
of 13
International Journal of Cancer
|
September 23, 2006
Urinary biomarker profiling in transitional cell carcinoma
Nicholas P Munro, David A Cairns, Paul Clarke, et al.
Molecular and Cellular Biology
|
March 10, 2001
RNA trafficking signals in human immunodeficiency virus type 1
A J Mouland, H Xu, H Cui, et al.
Biomaterials
|
August 3, 2010
Long term culture of human embryonic stem cells on recombinant vitronectin in ascorbate free media
Andrew B J Prowse, Michael R Doran, Justin J Cooper-White, et al.
The Journal of Biological Chemistry
|
February 22, 2021
Mutational and biophysical robustness in a prestabilized monobody
Peter G Chandler, Li Lynn Tan, Benjamin T Porebski, et al.
Molecular Pharmaceutics
|
August 27, 2021
Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer
Yaowu He, Tashbib Khan, Thomas Kryza, et al.
Ebiomedicine
|
October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
Keith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
The Journal of Infectious Diseases
|
November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trial
Keith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Nature Structural & Molecular Biology
|
July 8, 2025
A nanobody-based therapeutic targeting Nipah virus limits viral escape
Ariel Isaacs, Guillermo Valenzuela Nieto, Xinghai Zhang, et al.
The Lancet. Infectious Diseases
|
April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
Keith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Molecular Psychiatry
|
November 1, 2022
SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein
Eduardo A Albornoz, Alberto A Amarilla, Naphak Modhiran, et al.
Page
of 13